Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2006

View Archived Issues

In vivo analysis of beta-lactamase inhibitor NXL-104

Database lock on SIMPADICO trial of Celacade

Crucell licenses STAR technology to Xoma for research

Takeda transfers BASF Takeda Vitamin shares to BASF Japan

Nippon Shinyaku grants Innovive license to NS-187 for CML

TMC-114/ritonavir POWER 2 clinical data and antiviral enhancement with Fuzeon

Preclinical profile of aminocandin presented at ICAAC

pSivida signs new evaluation agreements for new subsidiary

EpiCept completes merger with Maxim Pharmaceuticals

Phase I study to evaluate eniluracil plus 5-FU

AVI BioPharma gets allocation from 2006 defense appropriations act

ZIO-101 to begin phase I/II study in advanced melanoma

Treatment completed in pivotal TRIUMPH study of eculizumab in PNH

Xencor and Roche extend research collaboration

Gabapentin GR shows sustained pain relief without sedation

Study confirms effectiveness of synDNA vaccines in producing immunologic activity

iDESTRIN relieves signs and symptoms of dry eye syndrome in postmenopausal women

Vicuron discloses data on novel azetidine lincosamides

KCP-256: A novel glucose concentration-dependent potentiator of insulin secretion

HPW-RX2 shown to inhibit thrombin and thromboxane formation

Fast track designation for Valortim for anthrax

New approaches for HIV infection treatment disclosed in recent patent literature

New gastric acid antisecretory agents emerge from Altana R&D

Clinical data on brecanavir for HIV infection reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...